Kineta - Crunchbase Company Profile & Funding

Q: Where is Kineta's headquarters?

Kineta is located in Seattle, Washington, United States.

Q: Who invested in Kineta?

Kineta has 10 investors including Keiretsu Capital And Cheongbo Industrial Co. (CBI).

Q: When was the last funding round for Kineta?

Kineta closed its last funding round on obfuscated from a Post-IPO Equity round.

Overview

Kineta

Total Funding

obfuscation

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

See more interactive data and historical milestones on desktop for the best experience

About Kineta

CB Rank

59846

Kineta aims at developing edge therapeutics in autoimmune disease, viral disease, and chronic pain areas.

Acquired by

TuHURA Biosciences

Founded

obfuscation

Public

Post-IPO Equity

Seattle, Washington, United States

11-50

www.kinetabio.com

Biotechnology

Medical Device

Therapeutics

Funding Rounds

Post-IPO Equity

OBF

obfuscation

Post-IPO Equity

OBF

obfuscation

Post-IPO Equity

OBF

obfuscation

Key People

Charles Magness: Co-Founder,President
Past Role: KPI Therapeutics, CEO and President
Craig Philips: President
Past Role: KPI Therapeutics, COO

Details

Legal Name

Kineta, Inc.

Also Known As

Kineta One LLC

Operating Status

Closed

Stock Symbol

NASDAQ:KA

Company Type

For Profit

Founders

Charles Magness, Shawn Iadonato

About the Company

Kineta is a biotechnology company engaging in the discovery and development of antiviral therapies and immune-modulating drugs for the treatment of RNA viruses that include hepatitis C, influenza, West Nile virus, and the common cold.

Phone Number

(206)378-0400

Contact Email

info@kinetabio.com

Predictions & Insights

Products & Services

KVA12123

A monoclonal antibody targeting VISTA to reduce immunosuppression in the tumor microenvironment, used as an infusion therapy for advanced solid tumors.

Anti-CD27 Agonist Monoclonal Antibody

A fully human monoclonal antibody that activates CD27 to stimulate naïve T cells and natural killer cells, aiming to generate new anti-tumor immune responses.

Unlock More with Crunchbase Pro

Full access to financial & funding data on unlimited profiles
Export up to 2k results/month for analysis
Track market signals on competitors, products, and R&D
Preview private company insights and predictions

Financials

Company Funding

Funding Rounds

Investors

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Post-IPO Equity - Kineta	—	obfuscated obfuscation	—	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - Kineta	—	obfuscated obfuscation	—	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - Kineta	—	obfuscated obfuscation	—	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - Kineta	—	obfuscated obfuscation	—	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - Kineta	—	obfuscated obfuscation	—	Post-IPO Equity

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Post-IPO Equity - Kineta	—	obfuscated obfuscation	—	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - Kineta	—	obfuscated obfuscation	—	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - Kineta	—	obfuscated obfuscation	—	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - Kineta	—	obfuscated obfuscation	—	Post-IPO Equity
obfuscated obfuscation	Post-IPO Equity - Kineta	—	obfuscated obfuscation	—	Post-IPO Equity

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.

Investor Name	Lead Investor	Funding Round	Partners
Keiretsu Capital	—	Post-IPO Equity - Kineta	—
Keiretsu Capital	—	Post-IPO Equity - Kineta	—
Keiretsu Capital	—	Post-IPO Equity - Kineta	—
Keiretsu Capital	—	Post-IPO Equity - Kineta	—
Keiretsu Capital	—	Post-IPO Equity - Kineta	—